Download PDF
Aktuelle Neurologie 2008; 35(2): 65-69
DOI: 10.1055/s-2007-986223
Arzneimitteltherapie

© Georg Thieme Verlag KG Stuttgart · New York

Migränetherapie mit Almotriptan

Therapy for Migraine with AlmotriptaneS.  Filz1 , W.  H.  Jost1
  • 1Fachbereich Neurologie, Deutsche Klinik für Diagnostik, Wiesbaden
Further Information

Publication History

Publication Date:
29 October 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Triptane sind selektive 5-HT1B- und 5-HT1D-Rezeptoragonisten, die in der Akutbehandlung der Migräne eine wichtige Rolle spielen. Mittlerweile stehen sieben Triptane zur Verfügung, die sich alle als sicher und verträglich erwiesen haben. Bei Almotriptan handelt es sich um eines der neueren Präparate, welches in zahlreichen Studien zur Dosisfindung, Effektivität und Verträglichkeit untersucht wurde. Almotriptan zeichnet sich durch ein Wirkungsprofil aus, das mit Sumatriptan hinsichtlich der Schmerzlinderung, vollständigen Schmerzfreiheit und Wiederkehrkopfschmerzrate vergleichbar ist. Dabei liegt die Ansprechrate 2 Stunden nach Einnahme von Almotriptan zwischen 60 - 70 %. In Bezug auf die Verträglichkeit scheint eine Therapie mit Almotriptan einer Behandlung mit anderen Triptanen ebenbürtig und in einzelnen Belangen sogar überlegen zu sein. Die Nebenwirkungsrate von Almotriptan ist mit der Einnahme von Plazebo vergleichbar und betrifft dabei sowohl zentrale Symptome (Schwindel, Müdigkeit u. a.) wie auch „Brustsymptome” (Palpitationen, thorakales Engegefühl).

Abstract

Triptanes are selective 5-HT1B- and 5-HT1D-receptor agonists that play a key role in the acute management of migraine. Meanwhile we have seven triptanes at hand - all of them proven to be safe and tolerable. Almotriptane is one of the more recent preparations which has been scrutinized as to proper dosage, efficiency and tolerance in a great number of studies. With regard to alleviation of pain, complete analgesia and the rate of relapsing headaches, the profile of action displayed by almotriptane is commensurate with those of sumatriptane. The response rate of almotriptane two hours after intake varies between 60 and 70 %. As to tolerance, it would seem that almotriptane is equivalent, in some issues even superior, to the other triptanes in use. The rate of adverse effects incurred with almotriptane equals that of placebo concerning central symptoms (dizziness, fatigue etc.) that is, as well as „chest symptoms” (palpitations, thoracic constriction).

Schlüsselwörter

Migräne - Almotriptan - unerwünschte Wirkungen

Key words

migraine - almotriptane - side effects

Literatur

  • 1 Bou J, Domenech T, Puig J. et al . Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.  Eur J Pharmacol. 2000;  410 33-41
    CrossrefPubMedGoogle Scholar
  • 2 Goadsby P J, Lipton R B, Ferrari M D. Migraine-current understanding and treatment.  N Engl J Med. 2002;  346 257-270
    CrossrefPubMedGoogle Scholar
  • 3 Tfelt-Hansen P, De Vries P, Saxena P R. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy.  Drugs. 2000;  60 1259-1287
    CrossrefPubMedGoogle Scholar
  • 4 Dahlöf C G, Dodick D, Dowson A J, Pascual J. How does almotriptan compare with other triptanes? A review of data from placebo-controlled clinical trials.  Headache. 2002;  42 99-113
    CrossrefPubMedGoogle Scholar
  • 5 Cabarrocas X, Warrington S J, Jansat J M. et al . Pharmacokinetics and tolerability of oral almotriptan in the elderly (Abstract).  Cephalalgia. 1999;  19 363
    PubMedGoogle Scholar
  • 6 Cabarrocas X, Jansat J M, Ferrer P, Luria X. Pharmacokinetics of oral almotriptan during and outside a migraine attack (Abstract).  Cephalalgia. 2000;  20 417
    PubMedGoogle Scholar
  • 7 Garcia E, Cabarrocas X, Jansat J M. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5-HT1B/1D agonist, in healthy volunteers (Abstract).  Headache. 1998;  38 376
    PubMedGoogle Scholar
  • 8 Jansat J M, Costa J, Salva P. et al . Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.  J Clin Pharmacol. 2002;  42 1303-1310
    PubMedGoogle Scholar
  • 9 Fachinformation. Almogran® 12,5 mg. Stand April 2007. 
    Google Scholar
  • 10 Dahlöf C G, Pascual J, Dodick D W, Dowson A J. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from for randomized, double-blind, placebo-controlled clinical trials.  Cephalalgia. 2006;  26 400-408
    CrossrefPubMedGoogle Scholar
  • 11 Dahlöf C G, Tfelt-Hansen M D, Massiou H, Fazekas M D. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine.  Neurology. 2001;  57 1811-1817
    PubMedGoogle Scholar
  • 12 Dowson A J, Massiou H, Lainez J M, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.  Cephalalgia. 2002;  22 453-461
    CrossrefPubMedGoogle Scholar
  • 13 Martinez E, Cabarroccas X, Peris F. et al . Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine (Abstract).  Cephalalgia. 1999;  19 362
    PubMedGoogle Scholar
  • 14 Mathew N, Finlayson G, Smith T. et al, on behalf of the AEGIS Investigator Study Group . Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT® Early Migraine Intervention Study).  Headache. 2007;  47 189-198
    CrossrefPubMedGoogle Scholar
  • 15 Pascual J, Falk R M, Piessens F. et al . Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.  Cephalalgia. 2000;  20 588-596
    CrossrefPubMedGoogle Scholar
  • 16 Pascual J, Lainez J M, Leira R. et al . Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study.  Neurologia. 2003;  18 7-17
    PubMedGoogle Scholar
  • 17 Pascual J, Tranche S, Leira R. et al . Almotriptan in clinical practice: experience in primary care vs. neurology setting.  Headache. 2003;  43 525
    PubMedGoogle Scholar
  • 18 Diener H C. Satisfaction with almotriptan 12,5 mg for treating multiple migraine attacks: An observational study in routine clinical settings in Germany.  Headache. 2004;  44 470-471
    PubMedGoogle Scholar
  • 19 Lainez M J, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.  Eur J Neurol. 2007;  14 269-275
    CrossrefPubMedGoogle Scholar
  • 20 Diener H C, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.  Headache. 2005;  45 1-9
    CrossrefPubMedGoogle Scholar
  • 21 Goadsby P J, Vila C. „Act When Mild” (AWM) study: early vs. non-early almotriptan intervention in migraine; presented at the 16th Migraine Trust International Symposium (MTIS) in London, on 20 September 2006. 
    Google Scholar
  • 22 Mathew N. A long-term open-label study of oral almotriptan 12,5 mg for the treatment of acute migraine attacks.  Headache. 2002;  42 32-40
    PubMedGoogle Scholar
  • 23 Pascual J, Falk R, Docekal R. et al . Tolerability and efficacy of almotriptan in the long-term treatment of migraine.  Eur Neurol. 2001;  45 206-213
    CrossrefPubMedGoogle Scholar
  • 24 Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine.  Headache. 2003;  43 1075-1079
    CrossrefPubMedGoogle Scholar
  • 25 Pascual J, Cabarrocas X. Within-patient early vs delayed treatment of migraine attacks with almotriptan: The sooner the better.  Headache. 2002;  42 28-31
    CrossrefPubMedGoogle Scholar
  • 26 Diener H C, Landen H, Stauch K. Almotriptan in der Routine-Behandlung akuter Migräneattacken: Eine Post-Marketing-Studie mit 899 Patienten.  Nervenheilkunde. 2003;  22 365-368
    PubMedGoogle Scholar
  • 27 Dodick D W. Oral almotriptan in the treatment of migraine: safety and tolerability.  Headache. 2001;  41 449-455
    CrossrefPubMedGoogle Scholar
  • 28 Dodick D W, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.  Cephalalgia. 2004;  24 417-424
    CrossrefPubMedGoogle Scholar
  • 29 Massiou H, Pradalier A, Donnet A. et al . Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine-satisfaction with treatment: reality with Almotriptan study.  Eur Neurol. 2006;  55 198-203
    CrossrefPubMedGoogle Scholar
  • 30 Ferrari M D, Roon K I, Lipton R B. et al . Oral triptans (serotonin 5-HT1B/1Dagonists) in acute migraine treatment: A meta-analysis of 53 trials.  Lancet. 2001;  358 1668-1675
    CrossrefPubMedGoogle Scholar
  • 31 Ferrari M D, Goadsby P J, Roon K I, Lipton R B. Triptans (serotonin 5-HT1B/1Dagonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials.  Cephalalgia. 2002;  22 633-658
    CrossrefPubMedGoogle Scholar
  • 32 Cabarrocas X, Zayas J M, Suris M. on behalf of the Almotriptan Oral Study Group . Equivalent efficacy of oral almotriptan, a new 5-HT1B1D agonist compared with sumatriptan 100 mg.  Headache. 1998;  38 377-378
    PubMedGoogle Scholar
  • 33 Keam S J, Goa K L, Figitt D P. Almotriptan. A review of its use in migraine.  Drugs. 2002;  62 387-414
    PubMedGoogle Scholar
  • 34 Goadsby P J, Massiou H, Pascual J. et al . Almotriptan and zolmitriptan in the acute treatment of migraine.  Acta Neurol Scand. 2007;  115 34-40
    PubMedGoogle Scholar
  • 35 Gendolla A. Klinisches Profil und praktischer Einsatz von Almotriptan.  Cephalalgia. 2004;  24 16-23
    PubMedGoogle Scholar
  • 36 Anon X. Almogran (almotriptan maleate) tablets. Summary of Product Characteristics. 2003
    Google Scholar
  • 37 Cabarrocas X, Salva M. Almotriptan has no pharmacokinetic/pharmacodynamic interaction with ethanol (Abstract).  Cephalalgia. 2002;  22 605
    PubMedGoogle Scholar
  • 38 Cabarrocas X, Macher J P. Lack of pharmacokinetic interaction between almotriptan and oral contraceptives: a double-blind, placebo-controlled, crossover study in healthy female volunteers (Abstract).  Cephalalgia. 2003;  23 715
    PubMedGoogle Scholar

Dr. med. Svenja Filz

Fachbereich Neurologie, Deutsche Klinik für Diagnostik

Aukammallee 33

65191 Wiesbaden

Email: filz.neuro@dkd-wiesbaden.de